跳转至内容

尊敬的客户:

目前国际形势复杂多变,关税政策尚不明朗,这可能对我们的产品价格产生一定影响。在此情况下,我们希望就订单事宜与您进行友好沟通。

基于当前的不确定性,如果您选择在此期间下单,我们将保留根据实际情况调整价格的权利。同时,我们也理解市场变化可能给您带来的困扰,因此如果在订单实际发货前因关税政策变动导致价格出现较大波动,默克将与您进行协商讨论并视情况对订单进行调整或取消。

Merck
CN
所有图片(1)

主要文件

安全信息

20032

Supelco

ORBO 活性硅胶管

W,W,W separators, O.D. × L 8 mm × 75 mm, pkg of 50 ea

别名:

ORBO Activated Silica Gel Tube

登录查看公司和协议定价

选择尺寸

1 EA
¥16,094.23

¥16,094.23


国内现货,预计发货时间2025年4月27日详情


获取大包装报价

选择尺寸

变更视图
1 EA
¥16,094.23

About This Item

UNSPSC代码:
47131900

¥16,094.23


国内现货,预计发货时间2025年4月27日详情


获取大包装报价

物料

W,W,W separators
silica gel

Agency

NIOSH 2007

产品线

ORBO

组成

Bed A, 300 mg
Bed B, 150 mg

包装

pkg of 50 ea

制造商/商品名称

ORBO 506

技术

active air sampling: suitable

外径 × 长度

8 mm × 75 mm

基质

Activated silica gel

粒径

45-60 mesh

正在寻找类似产品? 访问 产品对比指南

比较类似商品

查看完整比较结果

显示差异

1 of 4

此商品
59305U59304U59246U
separation technique

ion exclusion

separation technique

ligand exchange

separation technique

ion exclusion

separation technique

ion exclusion

particle size

9 μm

particle size

9 μm

particle size

9 μm

particle size

9 μm

matrix

sulfonated polystyrene/divinylbenzene, spherical particle platform, polymeric

matrix

sulfonated polystyrene/divinylbenzene, spherical particle platform, polymeric

matrix

sulfonated polystyrene/divinylbenzene, spherical particle platform, polymeric

matrix

sulfonated polystyrene/divinylbenzene, spherical, polymeric

product line

SUPELCOGEL

product line

SUPELCOGEL

product line

SUPELCOGEL

product line

SUPELCOGEL

agency

suitable for USP L17

agency

suitable for USP L19

agency

suitable for USP L17

agency

suitable for USP L17

technique(s)

HPLC: suitable

technique(s)

HPLC: suitable

technique(s)

HPLC: suitable

technique(s)

HPLC: suitable

一般描述

  • ORBO 506 Activated Silica Gel (45/60) 300/150 mg solvent desorption tube is designed for gas and vapor sampling.
  • It contains two beds of the same selective adsorbent separated by glass wool or foam.
  • Dual-layer or two-bed construction of the tube allows for any sample breakthrough to be captured in the smaller back-up bed.

法律信息

ORBO is a trademark of Sigma-Aldrich Co. LLC

储存分类代码

11 - Combustible Solids

WGK

nwg

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

  • 历史批次信息供参考:

    分析证书(COA)

    Lot/Batch Number

    It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

    如需帮助,请联系 客户支持

    已有该产品?

    在文件库中查找您最近购买产品的文档。

    访问文档库

    A Orbo et al.
    International journal of oncology, 5(3), 619-625 (1994-09-01)
    About 50% of the cases with invasive carcinoma of the uterine cervix occurs before menopause. Cyclic changes of sex steroids may therefore interfere with the ratio between extracellular levels of cGMP and cAMP (cGMP(ex)/cAMP(ex)). This ratio has been proposed as
    H Stalsberg et al.
    Virchows Archiv. A, Pathological anatomy and histopathology, 414(5), 415-422 (1989-01-01)
    The autopsies of 12 victims from two snow avalanches in North-Norway are reported. Supportive evidence from non-autopsied and surviving victims is included. Consistent autopsy findings were prominent lung oedema, moderate cerebral oedema, extreme contraction of the left ventricle, petechiae in
    Anne Ørbo et al.
    The Journal of steroid biochemistry and molecular biology, 113(1-2), 139-149 (2009-01-14)
    Patients with endometrial hyperplasia representing preliminary stages of endometrial cancer have shown to respond to therapy in 100% of the cases when treated with levonorgestrel-impregnated intrauterine device. Anti-proliferative effect has also been reported after application of an anti-progestin impregnated intrauterine
    Anne Beate Vereide et al.
    Gynecologic oncology, 97(3), 740-750 (2005-05-12)
    The aim of the study was to investigate apoptosis as a growth regulatory mechanism of gestagen in endometrial precancers and to compare differences in the apoptotic cascade after high and low dose gestagen regimens. Pre- and post-treatment paraffin-embedded endometrial hyperplasia
    A Ørbo et al.
    BJOG : an international journal of obstetrics and gynaecology, 123(9), 1512-1519 (2015-12-03)
    To investigate relapse rates after the successful treatment of patients with non-atypical endometrial hyperplasia who were randomised to either a levonorgestrel-impregnated intrauterine system (LNG-IUS; Mirena(®) ) or two regimens of oral medroxyprogesterone acetate (MPA) after primary histological response. A multicentre

    我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

    联系客户支持